Clinical Trials (Phases I–IV)

Design, endpoints, enrollment, interim reads, and post‑market surveillance.

  • 4 Tracked terms
  • Last 30 days Feed window
Search within this topic Ask AI about this topic All topics

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Clinical Trials (Phases I–IV)


clinicaltrialsarena.com > features > taihos-cmo-dr-keer-positive-phase-iii-rezilient3-data

Taiho’s CMO Dr Keer on positive REZILIENT3 data for zipalertinib combo

2+ day, 42+ min ago   (600+ words) Taiho Oncology chief medical officer (CMO) Dr Harold Keer recently discussed with Srivani Venna the outcomes from the Phase III REZILIENT3 trial of zipalertinib and chemotherapy. Taiho Oncology chief medical officer (CMO) Dr Harold Keer recently discussed with Srivani Venna the…...


clinicaltrialsarena.com > news > endeavors-taladegib-study-meets-endpoints

Endeavor’s Phase IIb IPF study of taladegib meets endpoints

4+ hour, 32+ min ago   (330+ words) Endeavor BioMedicines has reported that its Phase IIb WHISTLE-PF clinical trial assessing taladegib (ENV-101) achieved its primary and several key secondary endpoints in idiopathic pulmonary fibrosis (IPF) patients. The double-blind, randomised, dose-ranging, placebo-controlled, multi-centre trial evaluated 213 participants with IPF over…...


thepharmaletter.com > biotech-news > endeavor-s-hedgehog-inhibitor-taladegib-meets-endpoint-in-phase-iib-ipf-trial

Endeavor’s Hedgehog inhibitor taladegib meets endpoint in Phase IIb IPF trial - The Pharma Letter

4+ hour, 29+ min ago   (14+ words) Endeavor’s Hedgehog inhibitor taladegib meets endpoint in Phase IIb IPF trial The Pharma Letter...


stocktitan.net > news > GKOS > glaukos-announces-positive-topline-results-from-phase-4-prospective-k6ciuz36c003.html

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

3+ hour, 38+ min ago   (222+ words) The trial randomized 149 study eyes, assigning 74 to iDose TR with cataract surgery and 75 to cataract surgery alone. iDose TR in Combination with Cataract Surgery Demonstrated Robust Mean IOP Reduction of 11.1 mmHg and Favorable Safety Profile Through 3 Months iDose TR also…...


kdhnews.com > online_features > press_releases > argenx-announces-positive-topline-results-from-phase-2-study-of-fb102-in-celiac-disease > article_202da2ca-a88b-5767-81c7-fcbf0355aa9c.html

argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

1+ day, 9+ hour ago   (314+ words) October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the Phase 2 study evaluating FB102, a first-in-class CD122 inhibitor, in adults with celiac disease. These results represent the first clinical…...


clinicaltrialvanguard.com > news > tenax-pauses-level-2-enrollment-to-narrow-tnx-103-patient-selection

Tenax Pauses LEVEL-2 Enrollment to Narrow TNX-103 Patient Selection

8+ hour, 1+ min ago   (370+ words) Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Tenax Pauses LEVEL-2 Enrollment to Narrow TNX-103 Patient Selection The move is a…...


marketscreener.com > news > lakefront-biotherapeutics-gamgertamig-has-meaningful-opportunity-in-rare-autoimmune-diseases-rbc-s-ce785ad9de80f02d

Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says

22+ hour, 44+ min ago   (52+ words) Lakefront Biotherapeutics has a meaningful opportunity with its asset gamgertamig for the treatment of rare autoimmune diseases, RBC Capital Markets said in a note Wednesday. Gamgertamig has... Biotechnology & Medical Research Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases,…...


bioengineer.org > drug-repurposing-finds-igf1r-inhibitor-that-reverses-radioresistance-in-head-and-neck-cancer

Drug Repurposing Finds IGF1R Inhibitor That Reverses Radioresistance in Head and Neck Cancer

7+ hour, 11+ min ago   (655+ words) Researchers in Taiwan mapped a 25-microRNA regulatory network driving radioresistance in head and neck cancer and used transcriptome-guided drug repurposing to identify the IGF1R inhibitor I-OMe-AG-538 as a promising radiosensitizer....


openpr.com > news > 4655784 > natural-killer-cell-lymphoma-clinical-trial-pipeline-emerging

Natural Killer Cell Lymphoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight

19+ hour, 7+ min ago   (93+ words) The Natural Killer Cell Lymphoma clinical trial analysis report delivers important insights into ongoing research on 100 pipeline Natural Killer Cell Lymphoma Drugs clinical strategies upcoming therapeutics and commercial analysis Albany US On October 08 2026 DelveInsight s Natural Killer... Natural Killer Cell…...


markets.businessinsider.com > news > stocks > sionna-therapeutics-to-advance-sion-451-sion-2222-into-ascension-cf-poc-trial-1036544972

Sionna Therapeutics to advance SION-451 + SION-2222 into AscenSION CF POC trial

13+ hour, 21+ min ago   (330+ words) Sionna Therapeutics (SION) announced plans to advance SION-451 + SION-2222, its preferred proprietary dual combination, into the AscenSION CF Ph... Sionna Therapeutics to advance SION-451 + SION-2222 into AscenSION CF POC trial Sionna Therapeutics (SION) announced plans to advance SION-451 + SION-2222, its…...